Giuseppe
Emeritus
[Source: The Lancet, full text: (LINK). Extract, edited.]
------
The Lancet, Early Online Publication, 12 December 2011
doi:10.1016/S0140-6736(11)61845-X
β-agonists for ARDS: the dark side of adrenergic stimulation?
Original Text
B Taylor Thompson
In The Lancet , Fang Gao Smith and the BALTI-2 study investigators report the findings of their phase-3 randomised trial of intravenous salbutamol for acute respiratory distress syndrome (ARDS). The trial, based on reliable preclinical evidence and an encouraging phase-2 trial, was stopped early because of safety concerns. β-agonists had been an appealing therapeutic option for ARDS in view of extensive clinical experience, low cost, and an excellent safety profile when used for patients with obst (...)
-doi:10.1016/S0140-6736(11)61845-X
β-agonists for ARDS: the dark side of adrenergic stimulation?
Original Text
B Taylor Thompson
In The Lancet , Fang Gao Smith and the BALTI-2 study investigators report the findings of their phase-3 randomised trial of intravenous salbutamol for acute respiratory distress syndrome (ARDS). The trial, based on reliable preclinical evidence and an encouraging phase-2 trial, was stopped early because of safety concerns. β-agonists had been an appealing therapeutic option for ARDS in view of extensive clinical experience, low cost, and an excellent safety profile when used for patients with obst (...)
------